Zymeworks (ZYME) has released an update.
Zymeworks Inc., a clinical-stage biotech company, is slated to present at the TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference in March 2024. These conferences will feature one-on-one meetings and discussions showcasing Zymeworks’ advancements in biotherapeutics for challenging diseases, including their lead product candidate, zanidatamab. The events will be accessible via webcasts on the company’s investor relations website.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
